| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -25,336 | -17,152 |
| Stock-based compensation expense | 1,464 | 968 |
| Amortization of right to use lease asset | 12 | 12 |
| Non-cash interest expense | 911 | 696 |
| Change in fair value of derivative liabilities | 3,326 | 1,121 |
| Prepaid expenses and other assets | -895 | -428 |
| Accounts payable, accrued expenses and other liabilities | -3,584 | -3,239 |
| Accrued interest on convertible debt - related party | 4,479 | 2,875 |
| Net cash from operating activities | -17,833 | -14,291 |
| Net proceeds from exercise of common stock options and warrants | 1,167 | 724 |
| Net proceeds from issuance of common stock | 2,071 | 1,218 |
| Net proceeds from convertible line of credit related party | 11,000 | 11,000 |
| Net cash flows from financing activities | 14,238 | 12,942 |
| Net (decrease)/increase in cash and cash equivalents | -3,595 | -1,349 |
| Cash and cash equivalents at beginning of period | 15,120 | - |
| Cash and cash equivalents at end of period | 11,525 | - |
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)